Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)
Sponsor: Gemeinsamer Bundesausschuss (G-BA)
Terminated
The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient.
This PHASE3 trial investigates Multiple Myeloma and is currently terminated or withdrawn. Gemeinsamer Bundesausschuss (G-BA) leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Terminated PHASE3
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2023 — May 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gemeinsamer Bundesausschuss (G-BA)
- Staburo GmbH
- Universitätsklinikum Hamburg-Eppendorf
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Augsburg, Germany , Berlin, Germany , Bonn, Germany , Chemnitz, Germany , Dresden, Germany , Düsseldorf, Germany , Essen, Germany , Frankfurt am Main, Germany , Freiburg im Breisgau, Germany and 17 more locations